Friday, August 31, 2012
Transition Therapeutics Inc., of Toronto, reported that its licensing partner, Elan Corp. plc, of Dublin, Ireland, has commenced a Phase II trial of oral ELND005 (scyllo-inositol) as an adjunctive maintenance treatment in patients with bipolar I disorder to delay the time to occurrence of mood episodes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.